Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

Report reveals CMOs in Italy concentrated in worst-hit COVID-19 regions

5
SHARES

According to findings, the majority of CMOs in Italy are found in the locations hit worst by COVID-19, meaning the pharma supply chain has been greatly impacted.

White pills being manufactured at CMO

A new report has revealed that lockdown has had a negative impact upon the pharmaceutical supply chain in Italy and that contract manufacturing organisations are mainly located in the regions with the most cases of COVID-19. 

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

According to Globaldata, Italy is a major active pharmaceutical ingredient (API) supplier to the global market and its stringent lockdown measures have caused disruption of the supply chains that relied on this manufacture.

CMOs in Italy

Credit: Globaldata

The report outlines that while the country is now looking to reduce these restrictions, as the rate of COVID-19 infections has fallen and pressure from businesses and economic damage continue to mount, without any available vaccine a second peak of cases could hit the country when restrictions are eased, further impacting pharma production.

Adam Bradbury, Associate Healthcare Analyst at GlobalData, said: “Italy is an attractive destination for foreign-owned pharma companies, with 59 percent of the Italian pharma industry being formed by these companies. Italy also has a large number of pharma CMO facilities. GlobalData’s Contract Service Provider database shows there are 148 CMOs with Italian facilities.”

The opportunities for CDMOs in the pharmaceutical industry…

Milan has the largest number of manufacturing facilities in Italy with 51 and Rome has the second largest number with seven. Large CMOs such as Albany Molecular Research and Recipharm AB have facilities based in Milan, which is the worst hit Italian region for COVID-19 prevalence. Varese and Bergamo are also present in the Northern region of Lombardy, indicating that the Northern region is a pharma powerhouse in the country. Both the Lazio and Tuscany regions where the rest of the top six cities are based currently have a far lower prevalence of COVID-19 infections than Lombardy, says the report.

Share via
Share via